Icon

Adempas - (0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral)

Riociguat Bayer
0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
None
Indicated for Treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
Yes
**** *** *** **** *** *** ***** ** **** **** ** **** ******* '*** (*** *, ****). ****** *** ****** ** ** ****** **** ********** *** ********* **** **** ***** *** ***** ** ********* *** *** *****. **** ****** ****** ****** *** *, **** *.*. ****** **** *********** ****** ** *** *******. *** **** ** **** *********. ****** '*** *** ***** ********* ** ** **** **, ****. ***** ** *** **** ******* *** *** *******. ********* ** *****'* *** ******, *** ******** ****** ** ******* ** *** ****** ** ******. **, **** ** *** ******** *** ****** *** ******* ****** ******.
Adempas Patent 1 Patent 2 Patent 3 Patent 4
**** ******* ******* *** ********* *** ********* (***** ******)
*** **** *** ********* ******* ******* *** ********* (***** ******)
******* ********* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* **** **, **** ******* **** *** ****** *** ****
*** **** *** \ ********* **** **, **** ******* ******** ******* ****** *** ****
******* *** \ ********* **** **, **** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : **** & *** **** ********** ******** ***** ***** *** **** ** **** ****** '*** (*** *, ****).
  2. *** **, **** : ***** ***** * **** ******* **** & *** **** ** ******** ***** ** ********.
  3. *** **, **** : ********** ********* **** **** *** ****** '*** (*** *, ****) *.*. **** ****** ** ****, **** **** ********* *** ****** ** ** ***** *** ********* ** ****'* ****
  4. *** **, **** : *** **** ******** ***** ***** *** **** ** **** ****** '***.
  5. *** **, **** : ***** ***** * **** ******* *** **** ** ****** '***.
  6. *** **, **** : ********** ********* **** ********* **** *** **** *** **** ******.
  7. :
  8. *** **, **** : ***** ***** ******* **** ******* *******, **** ************ ** ******* '*** *** '*** (***** ******) **** ******** ** *** **, ****
  9. *** *, **** : ***** ***** * ***** **** ******* *******, **** ************ ** ****** '*** (*** *, ****)
  10. *** **, **** : ***** *** ******* ******* ********* **********. ** ****** ** ** **********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.